OverviewSuggest Edit

Akari Therapeutics is a clinical-stage biopharmaceutical company. It develops inhibitors of acute and chronic autoimmune and inflammatory diseases, specifically the complement system, the eicosanoid or leukotriene system, and the bioamine system.

TypePublic
Founded2014
HQNew York, US
Websiteakaritx.com

Latest Updates

Employees (est.) (Feb 2020)13
Share Price (May 2020)$2.1 (+5%)

Key People/Management at Akari Therapeutics

Ray Prudo

Ray Prudo

Executive Chairman
Clive Richardson

Clive Richardson

Chief Executive Officer, Chief Operations Officer
Wynne Weston-Davies

Wynne Weston-Davies

Medical Director
Miles Nunn

Miles Nunn

Chief Scientific Officer
Show more

Akari Therapeutics Office Locations

Akari Therapeutics has offices in New York and London
New York, US (HQ)
24 W 40th St
New York, US
135 W 41st St 5th floor
New York, US
24 W 40th St 8th floor
London, GB
75, 76 Wimpole St, Marylebone
Show all (4)

Akari Therapeutics Financials and Metrics

Akari Therapeutics Revenue

Market capitalization (26-May-2020)

60.3m

Closing stock price (26-May-2020)

2.1
Akari Therapeutics's current market capitalization is $60.3 m.
Show all financial metrics

Akari Therapeutics Online and Social Media Presence

Embed Graph

Akari Therapeutics News and Updates

Akari Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights

Significant Clinical Progress Across Target Indications during 2019 and 2020 Year-to-Date

Akari Therapeutics, Plc Announces Closing of $9.5 Million Private Placement

NEW YORK and LONDON, March 04, 2020 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, today announced it had…

Akari Therapeutics Frequently Asked Questions

  • When was Akari Therapeutics founded?

    Akari Therapeutics was founded in 2014.

  • Who are Akari Therapeutics key executives?

    Akari Therapeutics's key executives are Ray Prudo, Clive Richardson and Wynne Weston-Davies.

  • How many employees does Akari Therapeutics have?

    Akari Therapeutics has 13 employees.

  • Who are Akari Therapeutics competitors?

    Competitors of Akari Therapeutics include SmartZyme, Centrexion and Servier.

  • Where is Akari Therapeutics headquarters?

    Akari Therapeutics headquarters is located at 24 W 40th St, New York.

  • Where are Akari Therapeutics offices?

    Akari Therapeutics has offices in New York and London.

  • How many offices does Akari Therapeutics have?

    Akari Therapeutics has 4 offices.